Company registration number 13244451 (England and Wales)
SYNGENSYS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
SYNGENSYS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
SYNGENSYS LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,802,083
1,015,278
Tangible assets
5
50,138
61,603
1,852,221
1,076,881
Current assets
Debtors
6
370,566
289,091
Cash at bank and in hand
317,695
508,141
688,261
797,232
Creditors: amounts falling due within one year
7
(851,840)
(23,548)
Net current (liabilities)/assets
(163,579)
773,684
Total assets less current liabilities
1,688,642
1,850,565
Creditors: amounts falling due after more than one year
8
(10)
(238,964)
Net assets
1,688,632
1,611,601
Capital and reserves
Called up share capital
9
157
137
Share premium account
2,149,916
1,634,355
Other reserves
(110,946)
Profit and loss reserves
(350,495)
(22,891)
Total equity
1,688,632
1,611,601
SYNGENSYS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 2 -
For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
Mr C G Gillespie
Director
Company registration number 13244451 (England and Wales)
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information
Syngensys Limited is a private company limited by shares incorporated in England and Wales. The registered office is Freeths Llp Fifth Floor, 3 St Paul's Place, 129 Norfolk Street, Sheffield, South Yorkshire, S1 2JE.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.
1.2
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes.
Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably.
1.3
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.
1.4
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives at the point of commercial viability on the following bases:
Development costs
Variable rates
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:
Computers
20% straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).
1.7
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.
1.8
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.9
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.10
Taxation
The tax expense represents the tax currently payable
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 5 -
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense.
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
1.15
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources.
Critical judgements
The following judgements have had the most significant effect on amounts recognised in the financial statements.
Valuation of convertible loan notes
The company has convertible loan notes in issue, the details of the loan are given in note 8.
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
14
8
4
Intangible fixed assets
Development costs
£
Cost
At 1 April 2024
1,015,278
Additions
786,805
At 31 March 2025
1,802,083
Amortisation and impairment
At 1 April 2024 and 31 March 2025
Carrying amount
At 31 March 2025
1,802,083
At 31 March 2024
1,015,278
5
Tangible fixed assets
Computers
£
Cost
At 1 April 2024
77,330
Additions
4,644
At 31 March 2025
81,974
Depreciation and impairment
At 1 April 2024
15,727
Depreciation charged in the year
16,109
At 31 March 2025
31,836
Carrying amount
At 31 March 2025
50,138
At 31 March 2024
61,603
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Corporation tax recoverable
227,837
214,835
Other debtors
142,729
74,256
370,566
289,091
7
Creditors: amounts falling due within one year
2025
2024
£
£
Convertible loans
349,900
Trade creditors
172,221
Taxation and social security
18,400
9,152
Other creditors
311,319
14,396
851,840
23,548
The convertible loan notes are owned by a trading partner of the company. The loan note carries interest at 8% and has a maturity date of 12 July 2025. The loan is convertible into ordinary shares in the company at the option of the holder at any time, with the value of the conversion terms to be offered at a 30% discount when compared to the market price at the time of the conversion. Because of this uncertainty, the loan is valued at an amount equal to amortised cost, which is a key judgement in the preparation of these financial statements.
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Convertible loans
238,954
Other creditors
10
10
10
238,964
9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and not fully paid
Ordinary Shares of 1p each
12,166
10,257
122
102
Founder Ordinary Shares of 1p each
3,500
3,500
35
35
15,666
13,757
157
137
SYNGENSYS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
9
Called up share capital
(Continued)
- 8 -
2025
2024
2025
2024
Preference share capital
Number
Number
£
£
Issued and fully paid
Preferred Ordinary Shares of 1p each
1,000
1,000
10
10
Preference shares classified as liabilities
10
10
On 27 June 2024, 1,909 Ordinary shares were issued at an aggregate nominal value of £19.09. The consideration received was £515,430.
10
Events after the reporting date
On 4th April 2025, a share allotment took place following an investment round which resulted in the issue of 577 Ordinary shares and 593 Growth shares, both with a nominal value of £0.01 per share.
The financial impact of this investment round is an increase in share capital and share premium of £10.77 and £249,270 respectively. Cash at bank and in hand increased by £249,281.
On 16th May 2025, a share allotment took place following another investment round which resulted in the issue of 2,574 Ordinary shares with a nominal value of £0.01 per share. An amount of £246,682 relating to this investment round was received in advance before the balance sheet date, and has been presented within other creditors due within one year.
The financial impacts of this investment round is an increase of share capital and share premium of £25.74 and £1,111,994 respectively. Cash at bank and in hand increased by £865,337, and other creditors due within one year decreased by £246,682.